Study Finds No Detected Pregnancy Risks From Early GLP-1 Exposure

Large Analysis Evaluates Periconceptional Exposure

Inadvertent exposure to glucagon-like peptide-1 (GLP-1) receptor agonists around conception is not linked to a clearly detectable increase in adverse outcomes for mothers or infants. Researchers at City St George's, University of London, led the systematic review and meta-analysis published in the journal Med.

The team analyzed data across 10 observational studies comprising 2,118,215 pregnancies. Among those records, 8,325 pregnancies involved maternal exposure to a GLP-1 receptor agonist around conception and within six months prior to a positive pregnancy test.

Assessed Health Outcomes for Mothers and Infants

Researchers evaluated multiple maternal and fetal complications across the exposed and unexposed groups. The analysis found no clearly detectable differences in rates of complication between cohorts.

The measured outcomes included miscarriage, stillbirth, congenital anomalies, preterm birth, gestational diabetes, and high blood pressure disorders of pregnancy. The review also observed no detectable increase in excessive maternal weight gain or infants born unusually small or large for gestational age.

• Miscarriage and stillbirth rates showed no detectable increase.
• Congenital anomalies and preterm delivery occurred at comparable frequencies.
• Incidence of gestational diabetes and hypertensive disorders remained similar to unexposed groups.
• Infant birth size distributions showed no measurable shifts.

Context of Current Clinical Guidance

Clinical guidelines advise women to stop taking GLP-1 receptor agonists before attempting conception. Medications in this class include semaglutide, sold under brand names such as Ozempic and Wegovy, and tirzepatide, marketed as Mounjaro.

Because many pregnancies are unplanned, women frequently take these medicines before realizing they have conceived. While current protocols recommend stopping treatment before a planned pregnancy due to scarce safety data, unintended exposures have raised clinical concerns.

Observational Design Leaves Safety Questions Open

The study authors emphasize that these results do not prove that GLP-1 receptor agonists are safe during pregnancy. Because the underlying data come from observational studies, the analysis can show associations but cannot demonstrate cause and effect.

Lead author Professor Asma Khalil stated that patients who discover an inadvertent exposure should contact their healthcare team rather than panic. Official recommendations to stop GLP-1 medications prior to planned conception remain unchanged.